This paper explores the differences and synergies between Traditional Chinese Medicine (TCM) and Western Medicine in treating Chronic Kidney Disease (CKD). CKD is a growing health issue worldwide, significantly impacting patients' lives and increasing the risk of heart disease and premature death. Western Medicine primarily addresses CKD through dialysis and medications like SGLT-2 inhibitors, which manage symptoms and slow disease progression but come with side effects and high costs. On the other hand, TCM offers a holistic approach that focuses on restoring the body's balance using herbal remedies, aiming to treat the root causes of CKD and improve overall well-being. The paper compares how Western Medicine's targeted treatments and TCM's holistic methods can complement each other. While Western approaches provide quick relief and clear clinical benefits, TCM's therapies can mitigate side effects, support kidney function, and reduce oxidative stress, particularly in late-stage CKD. The integration of both systems could offer a more effective, cost-efficient treatment strategy, improving the quality of life for CKD patients. The paper advocates for a combined approach, using the strengths of both Western and Traditional Chinese Medicine to offer a comprehensive treatment plan for CKD.

Traditional Chinese Medicine;Western medicine;Chronic Kidney Disease

[1] Jing Kaile and Du Yingjie (2021). "Progress in the Treatment of Diabetic Nephropathy with Integrated Traditional Chinese and Western Medicine." [2] Liu Shuning, Ding, Xu Yuqin, Kang Jie, Zhang Jinping, Shao Baoping (2021). "The Mechanism and Intervention of Astragaloside IV on Radiation-Induced Kidney Injury." Chinese Journal of Applied Physiology, 37(4): 429-432. [3] Wu Qunli, Yang Dan, and Liang Xiaochun (2020). "Experience in Treating Diabetic Nephropathy and Renal Insufficiency with Xiaochun Liang's Method of Tonifying the Spleen and Kidneys, Promoting Blood Circulation, and Expelling Toxins." Journal of Traditional Chinese Medicine, 61(01): 17-19. [4] Xu Qi, Fu Jia, and Han Rui (2020). "Research Progress on the Use of SGLT-2 Inhibitors in the Treatment of Diabetic Nephropathy." China Medical Herald, 17(8): 4. [5] Li, L., C. Li, Y. Zhou, Q. Xu, Z. Wang, X. Zhu and Y. Ba (2020). "Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials." Frontiers in pharmacology 11: 560920-560920. [6] Nakayama, M., S. Kabayama and M. Miyazaki (2024). "Application of Electrolyzed Hydrogen Water for Management of Chronic Kidney Disease and Dialysis Treatment-Perspective View." Antioxidants 13(1): 90. [7] Persson, F., R. Borg and P. Rossing (2021). "A narrative review of new treatment options for chronic kidney disease in type 2 diabetes." Annals of translational medicine 9(8): 716-716. [8] Säemann, M., D. Cejka, S. Schmaldienst, A. R. Rosenkranz and G. Mayer (2023). "Value of SGLT-2 inhibitors in the treatment of chronic kidney disease: Clinical and practical implications." Wiener Klinische Wochenschrift 135(3-4): 97-109. [9] Shen, S., H. Zhong, X. Zhou, G. Li, C. Zhang, Y. Zhu and Y. Yang (2024). "Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment." Pharmaceutical biology 62(1): 222-232. [10]Tarun, T., S. N. Ghanta, V. Ong, R. Kore, L. Menon, C. Kovesdy, J. L. Mehta and N. Jain (2024). "Updates on New Therapies for Patients with CKD." Kidney international reports 9(1): 16-28. [11]Zhao, M., Y. Yu, R. Wang, M. Chang, S. Ma, H. Qu and Y. Zhang (2021). "Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease." Frontiers in pharmacology 11: 619201-619201.

DOI： https://doi.org/10.62639/sspjinss01.20240102

Published： 2024